论文部分内容阅读
目的:探讨在冠心病患者中应用不同剂量阿托伐他汀钙治疗过程中不良反应情况。方法:选取2015年5月至2016年5月在化州市人民医院接受治疗的90例冠心病患者作为研究对象,入选患者根据治疗方案进行分组,其中观察组45例患者按照40 mg·d-1的高剂量使用阿托伐他汀钙进行治疗;对照组45例患者按照20 mg·d-1的常规剂量进行治疗,比较两组患者治疗过程中不良反应发生情况。结果:两组患者在治疗前,三酰甘油(TG)、血清总胆固醇(TC)、高密度脂蛋白(HDL)和低密度脂蛋白(LDL)各项指标比较,差异均无统计学意义(P>0.05);经治疗后,两组患者的各项指标均有明显改善,与治疗前比较,差异均具有统计学意义(P<0.05);治疗后组间各项指标比较,差异均无统计学意义(P>0.05);两组患者的不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:在冠心病患者中应用不同剂量阿托伐他汀钙治疗,对各项指标的改善程度差别不大,不良反应发生情况相近,在临床治疗中根据患者病情酌情选择使用剂量。
Objective: To investigate the adverse reactions in the treatment of atorvastatin with different dosages in patients with coronary heart disease. Methods: From May 2015 to May 2016, 90 patients with coronary heart disease treated in Huazhou People’s Hospital were enrolled in this study. The patients were divided into groups according to the treatment plan. The 45 patients in the observation group were treated with 40 mg · d- 1 high dose of atorvastatin calcium treatment; 45 patients in the control group according to the conventional dose of 20 mg · d-1 treatment were compared between the two groups of patients during treatment of adverse reactions. Results: There were no significant differences in TG, TC, HDL and LDL between the two groups before treatment (P <0.05) P> 0.05). After treatment, the indexes of both groups were significantly improved, compared with before treatment, the differences were statistically significant (P <0.05); after treatment, the indicators between the two groups were not significantly different Statistical significance (P> 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions: The application of different doses of atorvastatin calcium in patients with coronary heart disease has little difference in the improvement of various indexes and similar adverse reactions. In clinical treatment, the dose of atorvastatin is selected according to the patient’s condition.